Regorafenib potently blocks several protein kinases that are involved in tumor angiogenesis (VEGFRs 1–3), oncogenesis (BRAF, RAF, RET, KIT), metastasis (FGFR, PDGFR, VEGFR3) and tumor microenvironment (TME) signaling (Tie2, CSF1R). Here, CSF1R is linked to neoplasm.